塞德斯医疗公司宣布，其针对慢性自发性荨麻疹（CSU）的关键性三期临床试验的顶线数据，预计将于2026年9月或10月公布。与此同时，公司旗下针对其他适应症——症状性皮肤划痕症（SD）与寒冷性荨麻疹（Coldu）——的两项三期研究，患者入组工作目前均按计划顺利进行。
塞德斯医疗公司宣布，其针对慢性自发性荨麻疹（CSU）的关键性三期临床试验的顶线数据，预计将于2026年9月或10月公布。与此同时，公司旗下针对其他适应症——症状性皮肤划痕症（SD）与寒冷性荨麻疹（Coldu）——的两项三期研究，患者入组工作目前均按计划顺利进行。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.